spectral property data

NEWS 29 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 30 SEP 13 FORIS renamed to SOFIS
NEWS 31 SEP 13 INPADOCDB: New SDI frequency MONTHLY available now

NEWS EXPRESS 05 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:40:27 ON 14 SEP 2007

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

FILE 'REGISTRY' ENTERED AT 11:40:58 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 SEP 2007 HIGHEST RN 947061-18-9
DICTIONARY FILE UPDATES: 13 SEP 2007 HIGHEST RN 947061-18-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\phenylder.str



chain nodes :
8 9 10 11
ring nodes :
1 2 3 4 5 6 7 12 13 14 15 16
chain bonds :
1-7 1-8 8-9 9-10 10-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-16 12-13 13-14 14-15 15-16
exact/norm bonds :
1-2 1-6 1-8 2-3 3-4 4-5 5-6 8-9 9-10 10-11
exact bonds :
1-7
normalized bonds :
7-12 7-16 12-13 13-14 14-15 15-16

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:CLASS 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom
Generic attributes :
11:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 11: Limited
C,C6

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:41:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 43526 TO ITERATE

4.6% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 858062 TO 882978
PROJECTED ANSWERS: 821 TO 1789

L2 3 SEA SSS SAM L1

=> d scan

L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4-Piperazinedicarboxamide, N,N'-bis[[4-phenyl-1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI)
MF C46 H50 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 11:41:40 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep  7, 2007 (20070907/UP).

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

FILE 'REGISTRY' ENTERED AT 11:42:57 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 SEP 2007  HIGHEST RN 947061-18-9
DICTIONARY FILE UPDATES:  13 SEP 2007  HIGHEST RN 947061-18-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\phenylder2.str
```




```
chain nodes :
8  9  10  11  18  19  20  21
ring nodes :
1  2  3  4  5  6  7  12  13  14  15  16
chain bonds :
1-7  1-8  8-9  8-18  8-19  9-10  10-11  10-20  10-21
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-12  7-16  12-13  13-14  14-15  15-16
exact/norm bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-9  9-10
exact bonds :
1-7  1-8  8-18  8-19  10-11  10-20  10-21
normalized bonds :
7-12  7-16  12-13  13-14  14-15  15-16


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:CLASS  9:CLASS  10:CLASS
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  18:CLASS  19:CLASS  20:CLASS
21:CLASS
Generic attributes :
11:
Saturation              : Unsaturated
Number of Carbon Atoms  : less than 7
Type of Ring System     : Monocyclic

Element Count :
Node 11: Limited
    C,C6



L3      STRUCTURE UPLOADED

=> d 13
L3 HAS NO ANSWERS
L3              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l3
SAMPLE SEARCH INITIATED 11:43:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      955 TO ITERATE

100.0% PROCESSED      955 ITERATIONS                          7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        17246 TO    20954
PROJECTED ANSWERS:               7 TO      298

L4            7 SEA SSS SAM L3

=> d scan
```


L4 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanamide, N-phenyl-N-[1-(phenyl-1-[2-(2-pyridinyl)ethyl)-4-piperidinyl]-, monohydrochloride
MF C31 H33 N3 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanamide, N-(2-fluorophenyl)-N-[1-[2-(3-iodo-1H-pyrrol-1-yl)ethyl]-4-phenyl-4-piperidinyl]-, ethanedioate (9CI)
MF C26 H29 F I N3 O . x C2 H2 O4

CM 1



CM 2

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinamine, 1-[(3-acetylphenyl)methyl]-4-phenyl-N-(phenylmethyl)-, monohydrochloride
MF C33 H36 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 7 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanamide, N-(2-fluorophenyl)-N-[4-phenyl-1-[2-(1H-pyrrol-1-yl)ethyl]-4-piperidinyl]-, ethanedioate (9CI)
MF C26 H30 F N3 O . x C2 H2 O4

CM 1



CM 2

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=>
Uploading C:\Program Files\Stnexp\Queries\phenylder-CN.str



chain nodes :
8 9 10 11 18 19 20 21 26 27
ring nodes :
1 2 3 4 5 6 7 12 13 14 15 16
chain bonds :
1-7 1-8 8-9 8-18 8-19 9-10 10-11 10-20 10-21 11-26 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-12 7-16 12-13 13-14 14-15 15-16
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 9-10 26-27
exact bonds :
1-7 1-8 8-18 8-19 10-11 10-20 10-21 11-26
normalized bonds :
7-12 7-16 12-13 13-14 14-15 15-16

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:CLASS 20:CLASS
21:CLASS 26:CLASS 27:CLASS
Generic attributes :
11:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 11: Limited
C,C6

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR

O



Structure attributes must be viewed using STN Express query preparation.

=> s l5
SAMPLE SEARCH INITIATED 11:44:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 151 TO ITERATE

100.0% PROCESSED 151 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2283 TO 3757
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 11:45:09 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 7, 2007 (20070907/UP).

=> log hold
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.06 2.64

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:45:22 ON 14 SEP 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

```
LOGINID:SSPTADKO1625

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 12:37:57 ON 14 SEP 2007
FILE 'STNGUIDE' ENTERED AT 12:37:57 ON 14 SEP 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

FILE 'REGISTRY' ENTERED AT 12:38:04 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 SEP 2007  HIGHEST RN 947061-18-9
DICTIONARY FILE UPDATES:  13 SEP 2007  HIGHEST RN 947061-18-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\phenylder4.str
```




```
chain nodes :
8  9  10  11  18  19  20  21
ring nodes :
1  2  3  4  5  6  7  12  13  14  15  16
chain bonds :
1-7  1-8  8-9  8-18  8-21  9-10  10-11  10-19  10-20
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-12  7-16  12-13  13-14  14-15  15-16
exact/norm bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-9  9-10
exact bonds :
1-7  1-8  8-18  8-21  10-11  10-19  10-20
normalized bonds :
7-12  7-16  12-13  13-14  14-15  15-16


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:CLASS  9:CLASS  10:CLASS
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  18:CLASS  19:CLASS  20:CLASS
21:CLASS
Generic attributes :
11:
Saturation              : Unsaturated
Number of Carbon Atoms  : less than 7
Type of Ring System     : Monocyclic

Element Count :
Node 11: Limited
    C,C6



L7      STRUCTURE UPLOADED

=> d 17
L7 HAS NO ANSWERS
L7              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l7
SAMPLE SEARCH INITIATED 12:38:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      229 TO ITERATE

100.0% PROCESSED      229 ITERATIONS                          1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          3673 TO     5487
PROJECTED ANSWERS:                1 TO       80

L8            1 SEA SSS SAM L7

=> s l7 full
FULL SEARCH INITIATED 12:38:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4528 TO ITERATE

100.0% PROCESSED     4528 ITERATIONS                         27 ANSWERS
SEARCH TIME: 00.00.01

L9           27 SEA SSS FUL L7

=> d scan
```


L9 27 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinemethanamine, N-[(2-methoxyphenyl)methyl]-4-phenyl- (9CI)
MF [illegible]
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 27 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinemethanamine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-phenyl- (9CI)
MF C21 H22 F6 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 27 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Piperidinemethanamine, 1-butyl-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]-, dihydrochloride (9CI)
MF [illegible] . 2 Cl H



•2 HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> d his

     (FILE 'HOME' ENTERED AT 11:40:27 ON 14 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 11:40:58 ON 14 SEP 2007
L1             STRUCTURE UPLOADED
L2           3 S L1

     FILE 'STNGUIDE' ENTERED AT 11:41:40 ON 14 SEP 2007

     FILE 'REGISTRY' ENTERED AT 11:42:57 ON 14 SEP 2007
L3             STRUCTURE UPLOADED
L4           7 S L3
L5             STRUCTURE UPLOADED
L6           0 S L5

     FILE 'STNGUIDE' ENTERED AT 11:45:09 ON 14 SEP 2007

     FILE 'REGISTRY' ENTERED AT 12:38:04 ON 14 SEP 2007
L7             STRUCTURE UPLOADED
L8           1 S L7
L9          27 S L7 FULL

=> file caplus
FILE 'CAPLUS' ENTERED AT 12:38:52 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Sep 2007  VOL 147 ISS 13
FILE LAST UPDATED: 13 Sep 2007  (20070913/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l9
L10         11 L9

=> d scan
```



```
L10   11 ANSWERS   CAPLUS  COPYRIGHT 2007 ACS on STN
CC    1-3 (Pharmacology)
TI    4,4-Di-substituted Piperidine High-Affinity NK1 Antagonists:
      Structure-Activity Relationships and in Vivo Activity
ST    piperidine tachykinin NK1 receptor antagonist
IT    Tachykinin receptors
         (NK1 antagonists; structure-activity relationships and in vivo
activity
         of 4,4-disubstituted piperidine high-affinity antagonists)
IT    Structure-activity relationship
         (structure-activity relationships and in vivo activity of
         4,4-disubstituted piperidine high-affinity antagonists)
IT    158144-67-3P  158144-67-3P  158144-68-4P  158144-82-2P
      160376-01-2P  160376-02-3P  160376-52-1P  160376-94-3P
      160376-97-6P  160376-98-7P  160376-99-8P  160377-01-5P
      160377-05-9P  160377-06-0P  160377-10-6P  160377-11-7P
      160377-12-8P  160377-14-0P  160377-17-3P  160377-24-2P  160377-25-3P
      160377-26-4P  160377-27-5P  160377-31-1P  160377-37-7P  167853-52-3P
      167853-54-5P  167853-55-6P  167853-75-0P  216980-03-9P  216980-04-0P
      216980-05-1P  216980-06-2P  216980-07-3P  216980-09-5P  216980-11-9P
      RL: PAC (Pharmacological activity or effector, except adverse); BSU
(Biological
      study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
         (structure-activity relationships and in vivo activity of
         4,4-disubstituted piperidine high-affinity antagonists)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1)10
```

=> d cbib abs hitstr

L10 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
2005:470969 Document No. 143:26636 Preparation of 4-[(Arylmethyl)aminomethyl]piperidine-as inhibitors of NGF binding (nerve growth f. tor) to p75NTR (p75 neurotrophic) receptor for treating p75NTR related diseases. Bosch, Michael; Wagner, Jean (Sanofi-Synthelabo, Fr.). Fr. Demande FR 2862304 A1 20050603, 31 pp. (French). CODEN: FRXXBL. APPLICATION: FR 2003-14172 20031201.
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X = (CH2)n; n = 1-2; R1 = CF3; R2 = H, alkyl; R3 = (un)substituted pyrrolyl, 1,2,3-thiadiazolyl, pyrazinyl, etc.; and their salts, hydrates and solvates] were prepared as inhibitors of the binding of 1251 NGF to p75NTR (p75 neurotrophic) receptor and of the apoptosis induced by NGF (nerve growth factor) for treating p75NTR related diseases and pain. For example, II was prepared by reacting 1-[4-(aminomethyl)-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(2-pyrazinyl)-1-piperazinyl]-1-ethanone (preparation given) and 1-methyl-2-pyrrolecarboxaldehyde in THF in the presence of NaBH(OAc)3/AcOH. I inhibited the binding of 1251 NGF to p75NTR receptor with IC50 in the range of 10-11 M to 10-6 M at the biochem. level. I inhibited the pro-apoptic effect induced by NGF, via growing cells expressing preferentially p75NTR, with IC50 in the range of 10-11 M to 10-6 M at the cellular level.
IT 852906-43-1, 1-Phenyl-N-[[1-[[4-(pyrazin-2-yl)piperazin-1-yl]acetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]methanamine RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 4-[(arylmethyl)aminomethyl]piperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)
RN 852906-43-1 CAPLUS
CN 4-Piperidinemethanamine, N-(phenylmethyl)-1-[[4-pyrazinyl-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)

L10 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



=> d cbib abs hitstr 1-11

L10 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

2005:[illegible] Document No. 143:126636 Preparation of 4-[(Arylsulfonylaminomethyl)piperidinesas inhibitors of NGF binding (nerve growth factor) to p75NTR (p75 neurotrophic) receptor for treating p75NTR related diseases. Tepassi, Busch, Michael; Wagnon, Jean (Sanofi-Synthelabo, Fr.). Fr. Demande FR 2862968 A1 20050603, 31 pp. (French). CODEN: FAXXBL. APPLI: FR, 2003-14172 20031201.

GI

' STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT '

AB Title [illegible] I [wherein X = (CH2)n; n = 1-2; R1 = CF3; R2 = H, alkyl; R3 = (un)substituted pyrrolyl, 1,2,3-thiadiazolyl, pyrazinyl, etc.; and their salts, hydrates and solvates] were prepared as inhibitors of the binding of 125I-NGF to p75NTR (p75 neurotrophic) receptor and of the apoptosis induced by NGF (nerve growth factor) for treating p75NTR related diseases (no data). For example, II was prepared by reacting 1-[4-(anilinomethyl)piperidin-4-yl]-4-[3-(trifluoromethyl)phenyl]-1-piperazinyl-1-ethanone (preparation given) and 1-methyl-2-pyrrolecarboxaldehyde in THF in the presence of NaBH(OAc)3/AcOH. I inhibited the binding of 125I NGF to p75NTR receptor with IC50 in the range of 10-11 M to 10-6 M at the binding level. I inhibited the pro-apoptotic effect induced by NGF, via glial cells expressing preferentially p75NTR, with IC50 in the range of 10-11 to 10-6 M at the cellular level.

IT 852984-77-4, 1-Phenyl-N-[[1-[[4-(pyrazin-2-ylpiperazin-1-yl)-1-oxoacetyl]-4-[3-(trifluoromethyl)phenyl]piperidin-4-yl]methyl]methanamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel piperidine and cyclohexanecarbonitrile derivs. as enhancers for LDL receptor manifestation, hypolipidemics, and antiatherosclerotics)

RN 852984-77-4 CAPLUS

CN 4-Piperidinemethanamine, N-(phenylmethyl)-1-[(4-pyrazinyl-1-piperazinyl)acetyl]-4-[3-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)

L10 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L10 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

2005:134273 Document No. 142:430269 Preparation of novel piperidine and cyclohexanecarbonitrile derivatives effective in enhancing LDL receptor manifestation. Ban, Hitoshi; Uhmura, Satoshi; Tsuchiya, Norio; Asano, Shigeki (Mitsubishi Pharmaceuticals Co., Ltd., Japan). PCT Int. Appl. WO 2005[illegible], 209 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, [illegible], BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, [illegible], EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, TR, [illegible] JP 2004-[illegible] CODEN: PIXKD2. APPLICATION: WO 2004-JP15773 20041019. PRIORITY: JP 2003-[illegible] 20031021.

GI



AB Drugs for enhancing LDL receptor manifestation contains compds. represented by the following formula (I), prodrugs thereof, or pharmaceutically acceptable salts of either [m, n, p = 0-4, provided that 3≤m+n+p≤4; A = N, each (un)substituted CH; Y = each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic group, COY; R1 = H, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, 3- to 8-membered saturated heterocyclyl containing one (unsubstituted NH or O, aromatic [illegible]; R2-R4 = each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic group; R2+R3 = H, OH, each (un)substituted alkyl, alkenyloxy, alkynyloxy, aralkyl, heteroarylalkyl, aralkyloxy, or heteroarylalkyloxy; or one or a plural combination of R2 and R3, R4 and R5, or R5 and R7 = oxo; or R2 and R4 together = alkylene; two of R2-R5 are on the adjacent carbon atom to form a double bond; Z = H, OH, CO2H, cyano, phthalimido, halo, each (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or aromatic group, etc.] as active ingredients. These compds. are effective in enhancing low d. lipoprotein (LDL) receptor manifestation and in lowering blood concentration of LDL cholesterol and are useful as therapeutic agents for treating hyperlipemia and arteriosclerosis. Thus, 0.019 mL benzylamine was added to a suspension of 40 mg 4-(3-methoxyphenyl)-1,4'-bipiperidine-4-carbonitrile dihydrochloride and 92.6 mg K2CO3 in 1.0 mL DMF at room temperature, ice-cooled, and the resulting mixture was warmed to room temperature, stirred overnight, and quenched by adding water to give, after workup and

L10 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

silica gel chromatog., 15.6 mg 1'-benzyl-4-(3-methoxyphenyl)-1,1'-bipiperidine-4-carbonitrile (II). II at 10 μM and N-benzyl-4-(3-methoxyphenyl)-1-(pyridin-2-yl)piperidine-4-carbothioamidat 3 μM enhanced the LDL receptor activity by 135 and 155%, resp.

IT 850884-77-4P, N-Benzyl-1-[1-(2-methoxyphenyl)-4-(3-methoxyphenyl)piperidin-4-yl]methanamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel piperidine and cyclohexanecarbonitrile derivs. as enhancers for LDL receptor manifestation, hypolipidemics, and antiatherosclerotics)

RN 850884-77-4 CAPLUS

CN 4-Piperidinemethanamine, 1-(2-methoxyphenyl)-4-(3-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
2003:892609 Document No. 139:381374 Preparation of urea derivatives as
tachykinin antagonists. Hirshfield, Michael; Kerten, Suzanne Ross;
Lawthwaite, Russell Andrew; Pritchard, Martyn Clive; Rawson, David James;
Scheltrum, Robert Michael; Tsim, Po-Wai (Neurogen Corporation, USA).
PCT Int. Appl. WO 2003092670 A1 20031113, 227 pp. DESIGNATED STATES: W:
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SY, TM, TN, TR, TT, TZ, UA, UG, US, VC, VN, YU, ZA, ZM,
ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG, ZM, ZW. (English). CODEN: PIXXD2. APPLICATION: WO
2003-US12474 20030417. PRIORITY: GB 2002-10239 20020503; US 2002-399132P
20020725.

GI



I

AB R1(CH2)mCR3R4(CH2)nY(CH2)pCO(CH2)qNR(CH2)rR2[R1 = (un)substituted aryl, heteroaryl, CO2H, CONR2, NR2, OH, alkyl, cycloalkyl; m, n, p, q = 0-2; r = 0-4; Y = (un)substituted NR, CHR2; R2 = (un)substituted cycloalkyl, aryl, heteroaryl, aryloxy, alkyl, aralkyl, alkenyl; R3, R4 = H, alkyl; R3R4 = alkylene, heteroalkylene] were prepared for use as nonmenin antagonists in treatment of male and female sexual dysfunction, particularly female sexual arousal disorder and male erectile dysfunction. Thus, 2-pyridinylacetonitrile was treated with BrCH2CH2Br to give 1-(2-pyridinyl)cyclohexylacetonitrile which was reduced to the amine, reductively alkylated with 4-HOCOCH2CH3, and treated with 2,3-Cl2C6H3NCO and triphosgene to give the urea I. I had Ki of 2 nM for antagonism at the BB1 receptor.

IT 623567-82-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of urea derivs. as nonmenin antagonists)

RN 623567-82-8 CAPLUS

CN Urea, N'-(2,6-bis(1-methylethyl)phenyl)-N-[(1-methyl-4-phenyl-4-piperidinyl)methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L10 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
2002:913930 Document No. 137:325334 Preparation of aryl and diaryl piperidines as MCH antagonists. Hodson, Douglas W.; Gong, Tao; Hunter, Rachael C.; Gu, Meizhong; Babu, Suresh D.; Zhao, Yuefei (Pharmacopeia, Inc., USA). PCT Int. Appl. WO 2002088134 A1 20021024, 113 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, ZW. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US12474 20020418. PRIORITY: US 2001-283523P 20010412.

GI



I II

AB The title compds. [I; Ar1 = (un)substituted Ph, pyridyl, pyrimidyl, etc.; Z = P4, CH=4, S(O)=4, etc.; R2 = H, alkyl, alkyl substituted with cycloalkyl; R3 = H, alkyl, cycloalkyl, etc.; R4 = Ph, phenylalkyl], useful for treatment, prevention or amelioration of one or more of diseases associated with the MCH receptor, were prepared E.g., a 7-step synthesis of II, starting from 3,4-difluorophenyl isocyanate, which showed Ki of 11-100 nM against MCH, was given. This invention provides also pharmaceutical compns. containing one or more of the compds. I for treatment of eating disorders.

IT 473736-81-1P 473736-83-3P 473736-84-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl and diaryl piperidines as MCH antagonists)

RN 473736-81-1 CAPLUS

CN [1,1'-Biphenyl]-3-carbonitrile, 4''-[4-[[[(3,5-dichlorophenyl)methyl](aminoimethyl]-1-(2-methoxyethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 473736-83-3 CAPLUS

CN 4-Piperidinemethanamine, 4-(3'-chloro[1,1'-biphenyl]-4-yl)-N-[(3,5-dichlorophenyl)methyl]-1-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 473736-84-4 CAPLUS

CN Acetamide, N-[4'-[4-[[[(3,5-dichlorophenyl)methyl]amino]methyl]-1-(2-methoxyethyl)-4-piperidinyl][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)

L10 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L10 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
2001:78241 Document No. 134:131434 Preparation of substituted piperidines as nociceptin receptor ORL-1 agonists for use in treating cough. Tulshian, Deen; Ho, Ginny D.; Silverman, Lisa S.; Matasi, Julius J.; McLeod, Robbie L.; Hey, John A.; Chapman, Richard W.; Bercovici, Ana; Cuss, Francis M. (Schering Corporation, USA). PCT Int. Appl. WO 2001007050 A1 20010201, 95 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US1453 20000126. PRIORITY: US 1999-355771 19990726.

GI



I



II

AB The title compds. [I; X1 = (un)substituted alkyl, cycloalkyl, aryl, etc.; X2 = CH2, CH, (un)substituted NH2, etc.; or X1 = (un)substituted benzofused heterocyclyl and X2 = H; or X1 and X2 together form an optionally benzofused spiro heterocyclyl group; R1-R4 = H, alkyl; or (R1 and R2) or (R2 and R3) or (R3 and R4) together can form an alkylene bridge; Z1 = (un)substituted alkyl, aryl, heteroaryl, etc.; Z2 = H, Z1; Z3 = H, alkyl; or Z1-Z2, together with the carbon to which they are attached, form bicyclic saturated or unsatd. rings] and their pharmaceutically acceptable salts, useful as ORL-1 receptor agonists for the treatment of cough, alone or in combination with one or more agents for the treatment of cough, allergy or asthma symptoms, were prepared and formulated. Thus, reacting 4-hydroxy-4-phenylpiperidine with 4-nitrobenzenesulfonyl chloride in the presence of K2CO3 in CH3CN afforded 90% II which showed Ki of 13 nM against ORL-1 receptor binding.

IT 256938-07-5P 256938-26-8P 256938-27-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted piperidines as nociceptin receptor ORL-1 agonists for use in treating cough)

RN 256938-07-5 CAPLUS

L10 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 4-Piperidinemethanamine, 1-(diphenylmethyl)-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 256938-26-8 CAPLUS

CN 4-Piperidinemethanamine, 1-(diphenylmethyl)-4-phenyl-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl

RN 256938-27-9 CAPLUS

CN 4-Piperidinemethanamine, 1-(diphenylmethyl)-4-phenyl-N-[(3-(trifluoromethylphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl

L10 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
2000:48819 Document No. 132:137290 Preparation of piperidine derivatives as high affinity ligands for nociceptin receptor ORL-1. Tulshian, Deen; Ho, Ginny D.; Silverman, Lisa S.; Matasi, Julius J.; McLeod, Robbie L.; Hey, John A.; Chapman, Richard W.; Bercovici, Ana; Cuss, Francis M. (Schering Corporation, USA). PCT Int. Appl. WO 2000006549 A1 20000210, 88 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, GA, GN, GW, IE, IT, LU, MC, NL, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US14165 19990726. PRIORITY: US 1998-122878 19980727.

GI



I



II

AB Compds. of formula I [wherein: the dotted line represents an optional double bond; X1 = (un)substituted alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl; X2 = CHO, CH, optionally substituted amino, alkyl, or aryl; or X1 =(un)substituted benzofused heterocyclyl and X2 = H; or X1 and X2 together form an optionally benzofused spiro heterocyclyl group; R1, R2, R3 and R4 = independently H and alkyl, or (R1 and R4) or (R2 and R3) or (R1 and R3) or (R2 and R4) together can form an alkylene bridge of 1 to 3 carbon atoms; Z1 = (un)substituted alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, or CO2(alkyl or substituted amino) or CH; Z2 = H or Z1; Z3 = H or alkyl; or Z1, Z2 and Z3, together with the carbon to which they are attached, form bicyclic saturated or unsatd. rings] or pharmaceutically acceptable salt or solvate thereof useful as nociceptin

L10 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
receptor inhibitors for the treatment of pain, anxiety, cough, asthma, depression, and alc. abuse are disclosed. Compd. II showed the Ki value of 13 nM in an in vitro test for ORL-1 receptor binding assay. Formulations are given.
IT 256938-07-5P 256938-26-8P 256939-27-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine derivs. as high affinity ligands for nociceptin receptor ORL-1)
RN 256938-07-5 CAPLUS
CN 4-Piperidinemethanamine, 1-(diphenylmethyl)-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 256938-26-8 CAPLUS
CN 4-Piperidinemethanamine, 1-(diphenylmethyl)-4-phenyl-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 256938-27-9 CAPLUS
CN 4-Piperidinemethanamine, 1-(diphenylmethyl)-4-phenyl-N-[[3-(trifluoromethyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L10 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

L10 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
1998:642712 Document No. 130:12676 4,4-Disubstituted Piperidine High-Affinity NK1 Antagonists: Structure-Activity Relationships and In Vivo Activity. Stevenson, Graeme I.; Huscroft, Ian; MacLeod, Angus M.; Swain, Christopher J.; Cascieri, Margaret A.; Chicchi, Gary G.; Graham, Michael I.; Harrison, Timothy; Kelleher, Finian J.; Kurtz, Marc; Ladduwahetty, Tamara; Merchant, Kevin J.; Metzger, Joseph M.; MacIntyre, D. E.; Sadowski, Sharon; Sohal, Balwinder; Owens, Andrew P. (Department of Medicinal Chemistry Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Harlow Essex, CM20 2QR, UK). Journal of Medicinal Chemistry, 41(23), 4623-4635 (English) 1998. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.
AB Previously reported studies from these labs. describes the design of a novel series of high-affinity NK1 antagonists based on the 4,4-disubstituted piperidine ring system. Further structure-activity studies have now established that for high NK1 affinity the benzyl ether side chain must be 3,5-disubstituted and highly lipophilic, the optimal side chain being the 3,5-bis(trifluoromethyl)benzyl ether, I2 (hNK1 IC50 = 0.95 nM). Addnl. studies have shown that this class of NK1 antagonist tolerates a wider range of substituents on the piperidine nitrogen, including acyl (hNK1 IC50 = 5.3 nM) and sulfonyl (hNK1 IC50 = 5.7 nM) derivs. Following preliminary pharmacokinetic anal., two compds. were selected for in vivo study in the resiniferotoxin-induced vascular leakage model, both showing excellent profiles (ID50 = 0.22 and 0.28 mg/kg, resp.).
IT 158144-61-7P 158144-67-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PAC (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(structure-activity relationships and in vivo activity of 4,4-disubstituted piperidine high-affinity NK1 antagonists)
RN 158144-61-7 CAPLUS
CN 4-Piperidinemethanamine, N-[(2-methoxyphenyl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 158144-67-3 CAPLUS
CN 4-Piperidinemethanamine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

L10 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●2 HCl

L10 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
1994:[illegible] Document No. 121:205217
4-[alkoxymethyl/alkylsulfonylmethyl-1-(2-phenylpiperidine tachykinin receptor antagonists. MacLeod, Angus Murray, [illegible]ensman, Graeme Irvine (Merck Sharp and Dohme Ltd., UK). PCT Int. Appl., [illegible] pp. DESIGNATED STATES: W: AU, CA, JP, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. [illegible]. CODEN: PIXD2. APPLICATION: WO 1993-GB2535 19931210. PRIORITY: [illegible] 1992-26014 19921214; GB 1993-1726 19930702; GB 1993-14486 19930714.
GI



I

AB The title [illegible] (I; R1, R2 = (un)substituted C1-6 alkyl, alkenyl, alkynyl, [illegible]en, CH, NO2, CF3, etc.; R3 = H, (un)substituted alkyl [illegible], (un)substituted CO2R, (un)substituted CONR2, etc.; R5-R8 = H, Cl; [illegible]; X = NH, SO, SO2; R4 = H, alkyl, CHO, SO2alkylsulfonyl; n = 2-4; m = 2 when n = 2-3 and m = 0-1 when n = 4), useful as tachykinin receptor [illegible]nists (no data), are prepared Thus, 4-(2-methoxymethyl)-4-phenylpiperidine[illegible]hydrochloride, m.p. 184-[illegible], was prepared from 4-cyano-4-phenylpiperidine hydrochloride in 4 steps.
IT 158144-[illegible]
RL: PAC (Properties); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
([illegible]ion and reaction of, in preparation of tachykinin receptor antagonists)
RN 158144-[illegible] CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[(2-methoxyphenyl)methyl]methylamino]methyl]-4-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L10 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 158144-61-7P 158144-67-3P 158144-68-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as tachykinin receptor antagonist)
RN 158144-61-7 CAPLUS
CN 4-Piperidinemethanamine, N-[(2-methoxyphenyl)methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 158144-67-3 CAPLUS
CN 4-Piperidinemethanamine, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

L10 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



●2 HCl

RN 158144-[illegible] CAPLUS
CN 4-Piperidinemethanamine, N-[(3,5-dichlorophenyl)methyl]-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 158144-75-3 158144-75-3
RL: RACT (Reactant or reagent); RACT (Reactant or reagent)
(tachykinin receptor antagonist)
RN 158144-75-3 CAPLUS
CN 4-Piperidinemethanamine, N-[(2-methoxyphenyl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 158144-75-3 CAPLUS
CN 4-Piperidinemethanamine, N-[(3,5-dichlorophenyl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)

L10 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L10 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
1987:19227 Document No. 106:19227 Platelet aggregation inhibiting and anticoagulant effects of oligoamines. 1. N-(4-Piperidinyl)methanamines. Rehse, Klaus; Werner, Ulrich (Inst. Pharm., Freien Univ. Berlin, Berlin, 1000/33, Fed. Rep. Ger.). Archiv der Pharmazie (Weinheim, Germany), 319(6), 505-15 (German) 1986. CODEN: ARPMAS. ISSN: 0365-6233. OTHER SOURCES: CASREACT 106:19227.

GI



I

AB The piperidinomethanamines I (n = 0, 1, 2, 3; n = 1-6; R = H, p-ClC6H4, 2-naphthyl; R1 = H, Me; R2 = H, MeO, Cl; R3, R4 = H, MeO) (21 compds.) were prepared as platelet aggregation inhibitors. Thus, 1-(4-cyano-4-phenylpiperidino)-2-(4-chlorophenyl)-1-ethanone, prepared from 4-phenyl-4-cyanopiperidine and p-ClC6H4CH2COCl, was reduced with LiAlH4 to give I (R = O, n = 2, R = R1 = R3 = R4 = H, R2 = Cl) (II). The most potent compound II had an platelet aggregation inhibiting IC50 of 5.5 + 10-6 mol/L.

IT 105378-83-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and platelet aggregation inhibiting activity of)

RN 105378-83-4 CAPLUS
CN 4-Piperidinemethanamine, 1-[2-(4-chlorophenyl)ethyl]-N-[(4-chlorophenyl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)

L10 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

L10 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
1981:192048 Document No. 94:192048 Synthesis of certain 1-butyl-4-phenyl-4-arylmethylaminomethylpiperidines. Gutkowska, Boguslawa; Nowak, Teresa (Dep. Chem. Technol. Pharm. Prod., Zak. Med., Warsaw, 02-097, Pol.). Acta Poloniae Pharmaceutica, 37(2), 177-80 (Polish) 1980. CODEN: APPHAX. ISSN: 0001-6837. OTHER SOURCES: CASREACT 94:192048.

GI

I

AB Schiff bases prepared from 1-butyl-4-phenyl-4-aminomethylpiperidine and aldehydes were hydrogenated, in some cases without isolation, on Pt or Pd catalysts under elevated pressure and at room temperature to yield 52-92% title compds. [I; R = 2- and 4-HOC6H4, 4-ClC6H4, 4-H2NC6H4, 3,4,5-(MeO)3C6H2, 2-, 3-, and 4-pyridyl], isolated for the most part as hydrochlorides or picrates.

IT 77621-33-1P 77621-34-2P 77621-36-4P
77621-37-5P 77629-00-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 77621-33-1 CAPLUS
CN Phenol, 2-[[[1-butyl-4-phenyl-4-piperidinyl]methyl]amino]methyl]-(9CI) (CA INDEX NAME)



RN 77621-34-2 CAPLUS
CN 4-Piperidinemethanamine, 1-butyl-N-[(4-chlorophenyl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)

L10 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 77621-36-4 CAPLUS
CN 4-Piperidinemethanamine, N-[(4-aminophenyl)methyl]-1-butyl-4-phenyl-, compd. with 2,4,6-trinitrophenol (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 77621-35-3
CMF C23 H33 N3



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7

L10 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 77621-37-5 CAPLUS
CN 4-Piperidinemethanamine, 1-butyl-4-phenyl-N-[(3,4,5-trimethoxyphenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



•2 HCl

RN 77629-00-6 CAPLUS
CN Phenol, 4-[[[1-butyl-4-phenyl-4-piperidinyl]methyl]amino]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



•2 HCl

L10 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
1964:63715 Document No. 60:63715 Original Reference No. 60:11242f-h
Comparison of rat liver response to a coumarin administered in vivo versus
In vitro. Pool, Judith G.; Borchgrevink, C.F. (Stanford Univ., Palo Alto.
CA). American Journal of Physiology, 206(1), 229-38 (Unavailable) 1964. CODEN: AJPHAP. ISSN: 0002-9513.
AB Warfarin added to incubated liver slices inhibits the synthesis of factor VII (proconvertin) in proportion to the log of its concentration. It has the same
inhibitory effect on the transport and incorporation of amino acid into protein of the liver slices. This latter finding supports the concept that vitamin K has a role in oxidative phosphorylation and that coumarin compds., by antagonizing vitamin K, uncouple oxidative phosphorylation and
thus have a general effect on cell energy supply. However, the same effect was not seen in the liver of rats depleted of vitamin K. Liver slices from such animals produced little factor VII but they incorporated amino acid at the normal rate. Administration of Warfarin in vivo had the
same result as vitamin K depletion: a fall in circulating prothrombin complex but no decrease in either labeling of plasma proteins by intravenous [C-labeled amino acid or incorporation of amino acid into subsequently excised liver slices. There is a striking discrepancy between the action of Warfarin administered in vitro and that administered
in vivo.
IT 94682-3G-7, Piperidine, 4-[(benzylamino)methyl]-1-methyl-4-phenyl-
(antivenous system response to)

RN 94682-3G-7 CAPLUS
CN Piperidine, 4-[(benzylamino)methyl]-1-methyl-4-phenyl- (7CI) (CA INDEX NAME)

10539140.trn

```
=> FIL STNGUIDE
FILE 'STNGUIDE' ENTERED AT 12:39:54 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep  7, 2007 (20070907/UP).

=>

=>
Executing the logoff script...


=> LOG H

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 1.50     240.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00      -9.36

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:54:59 ON 14 SEP 2007
```